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Purpose: To explore the diffusion-tensor (DT) imaging–defined in-
vasive phenotypes of both isocitrate dehydrogenase (IDH-
1)–mutated and IDH-1 wild-type glioblastomas.
Materials and 
Methods:
Seventy patients with glioblastoma were prospectively re-
cruited and imaged preoperatively. All patients provided 
signed consent, and the local research ethics committee 
approved the study. Patients underwent surgical resec-
tion, and tumor samples underwent immunohistochem-
istry for IDH-1 R132H mutations. DT imaging data were 
coregistered to the anatomic magnetic resonance study 
and reconstructed to provide the anisotropic and isotro-
pic components of the DT. The invasive phenotype was 
determined by using previously published criteria and cor-
related with IDH-1 mutation status by using the Freeman-
Halton extension of the Fisher exact probability test.
Results: Nine patients had an IDH-1 mutation and 61 had IDH-1 
wild type. All of the patients with IDH-1 mutation had 
a minimally invasive DT imaging phenotype. Among the 
IDH-1 wild-type tumors, 42 of 61 (69%) were diffusively 
invasive glioblastomas, 14 of 61 (23%) were locally inva-
sive, and five of 61 (8%) were minimally invasive (P , 
.001).
Conclusion: IDH-mutated glioblastomas have a less invasive phenotype 
compared with IDH wild type. This finding may have im-
plications for individualizing the extent of surgical resec-
tion and radiation therapy volumes.
Published under a CC BY-NC-ND 4.0 license.
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prospectively recruited to this study be-
tween August 2011 and October 2014. 
All patients were approached if they 
had a good performance status (World 
Health Organization performance 
status 0–1) and a tumor that the oper-
ating neurosurgeon indicated was suit-
able for a maximal resection assisted 
by 5-aminolevulinic acid fluorescence 
guidance (17). Patients with metallic 
implants not compatible with MR im-
aging (two patients) or those who were 
severely claustrophobic (five patients) 
were excluded. Only two patients who 
were approached declined to take part 
in this study. All patients provided 
signed consent, and the local research 
ethics committee approved the study.
MR Imaging Studies
Before surgery, patients underwent im-
aging with a 3-T MR imager (Magnetom 
Trio; Siemens Healthcare, Erlangen, 
Germany) by using a standard 12-chan-
nel receive-head coil and transmission 
on the body coil. Imaging sequences in-
cluded conventional anatomic imaging 
sequences and DT imaging. The ana-
tomic sequences included the following: 
an axial precontrast T1-weighted 
sequence (repetition time [msec]/echo 
time [msec]: 500/8.6; number of sig-
nals acquired, one; section thickness, 4 
mm; intersection gap, 1 mm; in-plane 
resolution, 0.74 mm; field of view, 24 
3 24 cm; and imaging time, 4 minutes 
Invasion of glioma cells into the 
surrounding healthy brain is a cardinal 
feature of glioblastoma and is a ma-
jor cause of our failure to achieve lo-
cal control. This occult invasion cannot 
be identified at conventional anatomic 
magnetic resonance (MR) imaging (8–
10) and therefore has been difficult to 
study. Because the invasion primarily 
involves white matter tracts, the use of 
diffusion-tensor (DT) imaging to help to 
identify this white matter disruption has 
been investigated as a suitable imaging 
marker of invasion. DT imaging depicts 
differences in the peritumoral region of 
invasive gliomas that are not found in 
noninvasive meningiomas or metastases 
(11,12). Specimens from image-guided 
biopsies of these regions showed that 
DT imaging can accurately depict tu-
mor invasion (10,13) and can be used 
to predict the pattern of tumor pro-
gression (14). These DT imaging–de-
fined invasive regions undergo perfusion 
and spectroscopic changes that resem-
ble tumor (15). Through use of these 
methods, it is clear that about 20% of 
tumors have what has been described 
as a minimally invasive DT imaging phe-
notype (14), and these tumors have a 
longer time to progression (16).
We hypothesized that IDH-mutated 
glioblastomas will have DT imaging fea-
tures that suggest a less invasive phe-
notype than that observed in IDH wild-
type glioblastomas. This study sought 
to explore the DT imaging–defined in-
vasive phenotypes of both IDH-mutated 
and IDH wild-type glioblastomas.
Materials and Methods
Patients
Seventy patients with glioblastoma con-
firmed with histologic analysis were 
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Advance in Knowledge
 n This study of nine patients with 
glioblastoma and isocitrate dehy-
drogenase (IDH) mutations (nine 
of 70 [13%]) showed that the 
nine glioblastomas with IDH mu-
tations appeared to have a diffu-
sion-tensor imaging–defined, 
minimally invasive phenotype.
Implication for Patient Care
 n This study helped to improve un-
derstanding of the better progno-
sis of IDH-mutated glioblas-
tomas, and it may have future 
implications for individualizing 
the extent of surgical resection 
and radiation therapy volumes.
G lioblastoma is the most common and most aggressive primary tu-mor of the brain and is associated 
with an appalling prognosis. Recent de-
velopments in molecular biology chal-
lenged the traditional classification of 
glioblastoma on the basis of features 
observed with light microscopy, with a 
subclassification on the basis of molecu-
lar markers. The discovery of mutations 
of the isocitrate dehydrogenase (IDH) 
gene, an early event in the development 
of low-grade gliomas (1), led to the re-
alization that some glioblastomas have 
this mutation (2–4). Nearly 90% of IDH 
mutations that affect both the cytostolic 
form IDH, IDH-1, and, less commonly, 
the mitochondrial form, IDH-2, are 
point mutations (1,2), which are de-
tected with immunohistochemistry (5).
Patients with glioblastoma and IDH 
mutations have a better prognosis; 
their median survival is 31 months, 
compared with 15 months in patients 
with IDH wild type (3,6). The reason 
that mutations of IDH improve survival 
is not fully understood. Normally func-
tioning IDH appears to be important 
in protecting cells against the oxidative 
stress caused by radiation therapy or 
chemotherapy. Therefore, mutations 
of IDH may increase sensitivity to cel-
lular damage caused by radiation ther-
apy and chemotherapy. This does not, 
however, explain findings by Beiko et 
al (7), who demonstrated that com-
plete resection of the enhanced tumor 
leads to better survival in IDH-mutated 
compared with IDH wild-type glioblas-
tomas. The outcome was even better 
in the mutant group when the resec-
tion extended into the nonenhanced 
tumor. These findings suggest differ-
ences in the invasive behavior of IDH-
mutated tumors.
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Immunohistochemistry was per-
formed on slices in which the paraf-
fin was removed, after heat-induced 
antigen retrieval, to evaluate the pres-
ence or absence of the IDH-1 R132H 
mutation. Mutation-specific antibodies 
(Dianova, Hamburg, Germany) were 
used at a 1:20 dilution and were viewed 
by using a secondary antibody avidin-
based detection system. Cytoplas-
mic immunoreactivity was regarded 
as a positive reaction. Negative and 
positive control tissues were stained 
appropriately.
IDH Sequencing
In five patients who did not have an 
IDH-1 R132H mutation at immuno-
histochemistry analysis but had a 
minimally invasive phenotype defined 
at DT imaging, tumor samples were 
used for next-generation sequencing 
of rarer mutations that involved both 
IDH-1 and IDH-2. The tumor speci-
mens were reviewed and DNA was ex-
tracted from tumor-rich tissue. DNA 
was then amplified for 207 mutational 
hotspot regions in 50 cancer-asso-
ciated genes by using primers (Ion 
AmpliSeq Cancer Hotspot Panel v2; 
Thermo Fisher Scientific, Waltham, 
Mass), sequenced (Ion PGM System; 
Thermo Fisher Scientific), and an-
alyzed for mutation status (Torrent 
Suite Software and Ion Reporter 
Software; Thermo Fisher Scientific). 
Mutations of IDH-1 on exon 4, codon 
132, and mutations of IDH-2 on exon 
4, codon 172, were sought because 
mutations at these regions account 
for all other IDH mutations (3).
Statistical Analysis
Data were analyzed by using statistical 
software (SPSS version 22; IBM, Ar-
monk, NY), and P values of less than 
.05 indicated statistical significance. 
Differences in age between groups on 
the basis of IDH-1 mutation status were 
evaluated by using an independent sam-
ple t test. The frequency of the three 
different invasive phenotypes was com-
pared according to IDH-1 R132H status 
by using the Freeman-Halton extension 
of the Fisher exact probability test for a 
2 3 3 contingency table.
method has good intra- and interrater 
agreement.
One author (S.J.P., with 16 years 
of experience with DT imaging data 
and image analysis) classified the inva-
sive phenotype by using a modification 
of previously published classification 
system (14). Three invasive pheno-
types were identified on the basis of the 
following DT imaging data: (a) diffuse 
invasive phenotype, if the p abnormal-
ity exceeded the q abnormality by more 
than 1 cm in all directions (a distance 
used in previous postmortem studies 
[19,20]); (b) localized invasive pheno-
type, if the p abnormality exceeded the 
q abnormality by more than 1 cm in 
one particular direction; and (c) mini-
mal invasive phenotype, if the p abnor-
mality was similar to the q abnormality.
To confirm that changes in adja-
cent white matter tracts show invasion, 
small-point regions of interest were 
placed in the white matter adjacent to 
the tumor, as determined by the frac-
tional anisotropic maps. Measurements 
of p and q were performed and the tis-
sue signature plotted with the p value on 
the x-axis and the q value on the y-axis 
by using previously published methods 
(21). Examples are shown in Figures 1 
and 2. On the basis of previously pub-
lished studies, an increase of greater 
than 10% compared with contralateral 
white matter for the isotropic (p) com-
ponent and a reduction of greater than 
12% compared with contralateral white 
matter were considered statistically sig-
nificantly different (10,21).
Pathologic Assessment and IDH-1 R132H 
Immunohistochemistry
All patients underwent surgical resec-
tion of the tumor with the intention 
to maximally resect the tumor. Tumor 
samples were fixed in 10% formalin 
and embedded in paraffin wax. Slices 
that were 4–mm thick were cut and 
stained with hematoxylin and eosin for 
light microscopy. The diagnosis of glio-
blastoma was on the basis of the World 
Health Organization 2007 histopatho-
logic criteria: an infiltrative astrocytic 
neoplasm with high proliferative activ-
ity and microvascular proliferation, ne-
crosis, or both (22).
22 seconds); an axial fluid-attenuated 
inversion recovery sequence (7840/95; 
inversion time, 2500 msec; number of 
signals acquired, one; section thick-
ness, 4 mm; intersection gap, 1 mm; 
in-plane resolution, 0.7 mm; field of 
view, 22.4 3 16.8 cm; imaging time, 4 
minutes 28 seconds). DT imaging was 
performed with a single-shot spin-echo 
echo-planar imaging sequence (8300/98 
msec; section thickness, 2 mm; no gap; 
in-plane resolution, 2 mm [providing 
isotropic voxel size to allow three-di-
mensional appreciation of white mat-
ter]; 12 directions; b values: 350, 650, 
1000, 1300, and 1600 sec/mm2; field 
of view, 19.2 3 19.2 cm; and imaging 
time, 9 minutes 26 seconds).
After intravenous injection of 9 mL 
of gadobutrol (Gadovist, 1.0 mmol/mL; 
Bayer, Leverkusen, Germany) followed 
by a 20-mL saline flush, a three-dimen-
sional T1-weighted inversion recovery 
sequence was performed (magneti-
zation-prepared rapid gradient echo; 
2300/2.98; inversion time, 900 msec; 
number of signals acquired, one; sec-
tion thickness; 1 mm; no gap; in-plane 
resolution, 1 mm; field of view, 25.6 3 
24.1 cm; and imaging time, 9 minutes 
14 seconds).
Imaging Data Postprocessing
We performed data processing offline. 
DT imaging data were processed by 
using the FDT toolbox in FSL (FMRIB 
software; Oxford Centre for Functional 
MR Imaging of the Brain, Oxford, Eng-
land). For each voxel, the eigenvalues 
(l1, l2, and l3) were calculated and 
were used to construct fractional an-
isotropy and p and q maps by using 
the previously described methods and 
terminology (18). For each of the p 
and q maps, regions of interest were 
drawn by using software (ImageJ; Na-
tional Institutes of Health, Bethesda, 
Md) around the visible region of in-
creased isotropic diffusion (for the p 
abnormality) and decreased aniso-
tropic diffusion (for the q abnormal-
ity) by a neurosurgeon (S.J.P.) with 
15 years of experience outlining these 
abnormalities. This neurosurgeon was 
blinded to the IDH mutation status. 
Previous work (15) showed that this 
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DT imaging—a phenotype previously 
shown to be associated with a good 
prognosis. Because most patients with 
glioblastoma will die of local tumor 
progression, limited local invasion may 
contribute to the better prognosis ob-
served in IDH-mutated glioblastomas.
Previous studies (7,24,25) of imag-
ing correlates of IDH-mutation status 
showed that IDH status leads to a dif-
ferent distribution in tumor location. 
IDH-mutated tumors are commonly lo-
cated in the frontal lobe, whereas IDH 
confidence interval: 66.4%, 100%) and 
specificity of 92% (95% confidence in-
terval: 81.9%, 97.3%).
Discussion
Our study showed that in glioblastomas 
with the IDH-1 mutation, DT imaging 
showed features of a less invasive tu-
mor compared with IDH-1 wild-type 
glioblastomas. All the IDH-1–mu-
tated glioblastomas exhibited a min-
imally invasive phenotype defined at 
The diagnostic accuracy of a mini-
mally invasive phenotype to detect the 
IDH-1 R132H mutation was calculated 
by using a 2 3 2 contingency table, with 
95% confidence intervals calculated 
with the log method (23).
Results
Patients Studied
Seventy patients were recruited to this 
study. Nine of 70 patients (13%) had 
the IDH-1 R132H mutation (six men; 
median age, 45 years [range, 22.0–
59.6 years]) and 61 of 70 (87%) had 
IDH-1 wild type (49 men; median age, 
61.4 years [range, 31.4–73.0 years]). 
The group with the IDH-1 R132H mu-
tation was significantly younger than 
the group with wild type (P = .003). 
The tumors with IDH-1 mutation were 
in the frontal lobe (six of nine) or tem-
poral lobe (three of nine). The IDH-1 
wild-type tumors were in the frontal 
lobe (22 of 61), temporal lobe (21 of 
61), parietal lobe (11 of 61), and occip-
ital lobe (seven of 61).
Invasive Phenotypes and IDH-1 Status
For the entire cohort, 42 of 70 (60%) 
tumors were diffusely invasive glioblas-
tomas, 14 of 70 (20%) were locally in-
vasive, and 14 of 70 (20%) were mini-
mally invasive. Of the IDH-1 wild-type 
tumors, 42 of 61 (69%) were diffusively 
invasive glioblastomas, 14 of 61 (23%) 
were locally invasive, and five of 61 
(8%) were minimally invasive. In all 
nine patients with an R132H mutation, 
the tumors were minimally invasive. 
The difference in these distributions 
was significant (P , .001).
Further sequencing in the five of 61 
patients who were negative for IDH-1 
R132H and who had a minimally in-
vasive pattern revealed no rarer mu-
tations of IDH-1 or IDH-2, which sug-
gested that they had IDH wild-type 
tumors.
Minimal Invasive Phenotype Detection of 
IDH-1 R132H Mutation
Use of the minimally invasive pheno-
type as a diagnostic test for IDH mu-
tation had sensitivity of 100% (95% 
Figure 1
Figure 1: (a) Anisotropic (q) and isotropic (p) DT imaging maps in a 46-year-old man with IDH-mutated 
glioblastoma. The abnormality outlined within the anisotropic component (q, outlined by the blue line) is simi-
lar to the isotropic abnormality ( p, outlined by the red line). The diffusion tissue signature could be measured 
in white matter regions of interest adjacent to the tumor (red) and in a similar location in the contralateral 
hemisphere (blue). (b) The diffusion tissue signature in adjacent white matter shows that, compared with the 
contralateral white matter, these values are consistent with no invasion of the white matter tract.
Radiology: Volume 283: Number 1—April 2017 n radiology.rsna.org 219
NEURORADIOLOGY: Less Invasive Phenotype in Glioblastomas with Isocitrate Dehydrogenase–1 Mutation Price et al
of reduced tumor invasion in these 
IDH-mutated tumors.
At first glance, our results would 
appear to be contrary to those report-
ed by Baldock et al (29), who found 
that IDH-mutated tumors were more 
invasive. Those investigators calcu-
lated a biologic aggressiveness ratio 
(the r/D ratio) from estimating param-
eters to quantify the net proliferation 
rate (r) and tumor cell dispersion or 
diffusion rate (D). They found that 
glioblastomas with a IDH-1 mutation 
have a low r/D ratio, which suggests 
markedly dispersed tumor cells with 
a low central density of tumor cells. 
This may explain the postmortem find-
ing of dispersed R132H-positive cells 
throughout the brain (30). In real-
ity, imaging methods can depict only 
a high density of tumor cells. Biopsy 
studies have confirmed that within the 
isotropic (p) abnormality there was 
high density of tumor cells, with un-
detectable tumor cells outside of this 
region (10). Our findings show low tu-
mor cell density in the immediate peri-
tumoral region, a finding that agrees 
with mathematical modeling from Bal-
dock et al. Newer diffusion techniques, 
such as restriction spectrum imaging, 
that can differentiate restricted from 
hindered diffusion (31) may better 
reflect tumor cellularity in this peritu-
moral area.
The fact that the invasive margin 
of glioblastomas with IDH-1 mutation 
has lower cellular density might explain 
the improved outcome with extended 
resection beyond the contrast agent–
enhanced tumor into the unenhanced 
fluid-attenuated inversion recovery 
abnormality (7). Although this study 
failed to show a similar outcome in IDH 
wild-type tumors, recent studies pro-
vide some evidence that resection into 
noncontrast-enhanced tumor does im-
prove outcome (32). We conclude that 
in the absence of better imaging tech-
niques to distinguish between tumor 
and cerebral edema, extending resec-
tion into the fluid-attenuated inversion 
recovery region improves survival with-
out substantial postoperative morbidity. 
Our DT imaging method might provide 
a better target for resection into the 
distinct enhanced border is more likely 
to be observed in tumors with a IDH-
1 mutation (26), whereas other studies 
found no association with IDH-1 muta-
tion status (25). Studies that used diffu-
sion imaging found increased apparent 
diffusion coefficient in the peritumoral 
region, which suggested reduced cellu-
larity and angiogenesis in these regions 
(27). Perfusion imaging helped to con-
firm reduced perfusion in IDH-mutated 
tumors (28). This supports our finding 
wild-type gliomas are commonly found 
in insular regions (26). This frontal 
distribution may make these tumors 
more likely to be resectioned (7) and 
may also account for the improved out-
come. Additionally, it may also explain 
why our study recruited so many pa-
tients who had tumors with a IDH-1 
mutation, which were suitable for radi-
cal resection. Studies that observed the 
visual tumor margin provided mixed 
results. Some studies suggested that a 
Figure 2
Figure 2: (a) Anisotropic (q) and isotropic (p) DTI maps in a 59-year-old man with IDH wild-type glioblas-
toma. It shows that the isotropic abnormality ( p, outlined by the red line) is larger than the anisotropic com-
ponent (q, outlined by the blue line) in more than one direction, making it a diffuse phenotype. The diffusion 
tissue signature was measured in white matter regions of interest adjacent to the tumor (shown in red) and 
in a similar location in the contralateral hemisphere (shown in blue). (b) The diffusion tissue signatures con-
firm that there is an increase in the isotropic component (p) of the DT compared with the contralateral white 
matter, while the anisotropic component (q) is unchanged. This diffusion tissue signature fits tumor invasion.
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ology 2004;232(2):451–460.
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Evaluation of changes in gliomas structural 
features after chemotherapy using DTI-
based functional diffusion maps (fDMs): A 
preliminary study with intraoperative corre-
lation [abstr]. In: Proceedings of the Nine-
teenth Meeting of the International Society 
for Magnetic Resonance in Medicine. Berke-
ley, Calif: International Society for Magnetic 
Resonance in Medicine, 2011; 2411.
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imaging. Eur Radiol 2007;17(7):1675–1684.
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tion and quantification of magnetic resonance 
diffusion tensor imaging using the p:q tensor 
decomposition. Br J Radiol 2006;79(938): 
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diagnostic accuracy would retain a 
high specificity (91%) and sensitivity 
(70%).
In conclusion, we used DT imaging 
to study the invasive properties of the 
invasive margin of glioblastomas and 
have shown that glioblastomas with 
IDH-1 mutation exhibit a minimally in-
vasive DT imaging–defined phenotype. 
This finding may help to explain the 
good prognosis of this group of tumors 
and it supports the role of more exten-
sive local therapy for these tumors.
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